World journal of clinical oncology最新文献

{"title":"Cytochrome P450 3A gene family in gastric cancer: Unveiling diagnostic biomarkers and therapeutic targets for personalized treatment.","authors":"Jun-Kun Zhu, Jing Wang","doi":"10.5306/wjco.v16.i4.101548","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.101548","url":null,"abstract":"<p><p>The cytochrome P450 3A (<i>CYP3A</i>) gene family's role in early progression of gastric cancer was comprehensively investigated. Its potential as a therapeutic target was evaluated. Upon literature review, aberrant expression of the <i>CYP3A</i> gene family has a strong correlation with gastric cancer onset, although the precise underlying mechanisms remain unclear. To assess its potential as a biomarker for early diagnosis and a therapeutic target, we have provided a comprehensive review of the regulatory mechanisms governing <i>CYP3A</i> gene family expression in gastric cancer, as well as its relation with early tumor progression and the tumor microenvironment. The <i>CYP3A</i> gene family is crucial in the proliferation, migration, and invasion of gastric cancer cells and promotes cancer progression by modulating inflammatory responses and oxidative stress within the tumor microenvironment. Furthermore, genetic polymorphisms in <i>CYP3A</i>enzymes highlight its potential value in personalized medicine. Based on these findings, this paper explores the feasibility of developing inhibitors and activators targeting <i>CYP3A</i> enzymes and discusses potential applications in gene therapy. This research provides crucial theoretical support for the <i>CYP3A</i> gene family as an early diagnostic marker and therapeutic target for gastric cancer. In the future, multi-omics studies and large-scale clinical trials will be essential to advance clinical translation of these findings.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"101548"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of family history of breast disease on knowledge, attitudes, and breast cancer preventive practices among reproductive-age females.","authors":"Melaku Mekonnen Agidew, Niguss Cherie, Zemene Damtie, Bezawit Adane, Girma Derso","doi":"10.5306/wjco.v16.i4.101788","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.101788","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is one of the most prevalent causes of morbidity and mortality worldwide, presenting an increasing public health challenge, particularly in low-income and middle-income countries. However, data on the knowledge, attitudes, and preventive practices regarding breast cancer and the associated factors among females in Wollo, Ethiopia, remain limited.</p><p><strong>Aim: </strong>To assess the impact of family history (FH) of breast disease on knowledge, attitudes, and breast cancer preventive practices among reproductive-age females.</p><p><strong>Methods: </strong>A community-based cross-sectional study was conducted in May and June 2022 in Northeast Ethiopia and involved 143 reproductive-age females with FH of breast diseases and 209 without such a history. We selected participants using the systematic random sampling technique. We analyzed the data using Statistical Package for Social Science version 25 software, and logistic regression analysis was employed to determine odds ratios for variable associations, with statistical significance set at <i>P</i> < 0.05.</p><p><strong>Results: </strong>Among participants with FH of breast diseases, the levels of knowledge, attitudes, and preventive practices were found to be 83.9% [95% confidence interval (CI): 77.9-89.9], 49.0% (95%CI: 40.8-57.1), and 74.1% (95%CI: 66.9-81.3), respectively. In contrast, among those without FH of breast diseases, these levels were significantly decreased to 10.5% (95%CI: 6.4-14.7), 32.1% (95%CI: 25.7-38.4), and 16.7% (95%CI: 11.7-21.8), respectively. This study also indicated that knowledge, attitudes, and preventive practices related to breast cancer are significantly higher among participants with FH of breast diseases compared to those without HF breast diseases.</p><p><strong>Conclusion: </strong>Educational status, monthly income, and community health insurance were identified as significant factors associated with the levels of knowledge, attitudes, and preventive practices regarding breast cancer among reproductive-age females.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"101788"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple primary tumors patient developed microsatellite stable gastric cancer after cadonilimab treatment for liver cancer: A case report.","authors":"Si-Qi Luo, Li Dai, Yong-Jin Zhou, Tong He, Fang-Jie Wang, Xiang-Ren Jin, Qian Wang","doi":"10.5306/wjco.v16.i4.102418","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102418","url":null,"abstract":"<p><strong>Background: </strong>Multiple primary malignant tumors refer to the occurrence of two or more primary malignant tumors in the same organ or multiple organs or tissues at the same time or successively in the same patient, and can occur anywhere in the body. The treatment guidelines for patients with multiple primary malignant tumors are currently controversial.</p><p><strong>Case summary: </strong>A 51-year-old male patient with liver cancer and portal hypertension received 42 months of co-treatment with atezolizumab and bevacizumab. After that, the disease was rated stable disease. The patient was then diagnosed with gastric cancer. Since the patient was not sensitive to anti-programmed death ligand 1 immunosuppressive agents, a co-treatment with oxaliplatin, tegafur, apatinib, and cadonilimab was selected after multidisciplinary consultation and the patient's agreement. After four cycles of treatment, partial response and stable disease were observed in gastric and liver cancers, respectively. Surgical treatment was performed considering the high-risk factors of gastrointestinal bleeding in patients with gastroesophageal varices. Postoperative pathology showed that the Tumor Regression Grade was 1. Moreover, the genetic testing of postoperative tumor specimens indicated negative programmed death ligand 1 and microsatellite stability. In addition, the latest follow-up indicated an 8 and 40-month progression-free survival in gastric and liver cancer patients, respectively. Currently, the patient is receiving postoperative immunotherapy with cadonilimab.</p><p><strong>Conclusion: </strong>Cadonilimab not only treats microsatellite stability gastric cancer patients but can also be used for liver cancer treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102418"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature.","authors":"Lou-Lu Gao, Dong-Ni Gao, Hong-Tu Yuan, Wen-Qiang Chen, Jing Yang, Jie-Qiong Peng","doi":"10.5306/wjco.v16.i4.102297","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102297","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal neuroendocrine carcinoma (GI NEC) has a low incidence rate and poor prognosis. Most patients already have metastatic disease when they are diagnosed. Platinum chemotherapy is the main means of treating metastatic GI NECs. There is a lack of effective treatment methods after chemotherapy failure. Therefore, Therefore, selecting appropriate posterior-line treatment programs to improve the prognosis of patients is urgently needed.</p><p><strong>Case summary: </strong>A 64-year-old female was diagnosed with stage IV NEC of the rectum due to abdominal pain and rectal bleeding. After multiline chemotherapy, the condition progressed, and the patient was treated with a combination of camrelizumab and surufatinib. The efficacy evaluation revealed partial remission (PR) and stable conditions, with the expression of the tumor marker neuron-specific enolase (NSE) returning to normal. The adverse reactions were controllable, and the overall condition was good, with weight gain achieved in the past four years. Another 51-year-old female experienced recurrence and metastasis of a duodenal NEC after surgery. After multiline chemotherapy, she received sintilimab combined with surufatinib. The curative effect fluctuated between PR and stability. During treatment, she recovered from immune-related diabetes and later died due to deterioration of her condition. During the treatment, the patient's NSE level returned to normal.</p><p><strong>Conclusion: </strong>The combination of antiangiogenic targeted drugs and immunotherapy provides a new therapeutic approach for the treatment of metastatic GI-NECs.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102297"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and validation of a novel prognostic nomogram for patients with poorly differentiated gastric neuroendocrine neoplasms.","authors":"Ben-Long Zhang, Fei Peng, Li Li, Yun-He Gao, Zi-Jian Wang, Yi-Xun Lu, Lin Chen, Ke-Cheng Zhang","doi":"10.5306/wjco.v16.i4.102565","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102565","url":null,"abstract":"<p><strong>Background: </strong>The prognosis of patients with poorly differentiated gastric neuroendocrine neoplasms (PDGNENs) is dismal and related research is limited.</p><p><strong>Aim: </strong>To investigate the prognostic factors, and validate a novel prognostic nomogram for PDGNEN patients.</p><p><strong>Methods: </strong>We conducted a retrospective study using clinical and pathological data from PDGNEN patients treated at the First Medical Center of the Chinese PLA General Hospital from January 2000 to June 2023. Overall survival (OS) differences were assessed with the Log-rank test and Kaplan-Meier survival curves. Cox regression analysis identified independent risk factors for prognosis. Model performance was evaluated using Harrell's concordance index, receiver operating characteristic analysis, area under the curve, calibration curves, and decision curve analysis (UDC), including the area under the UDC.</p><p><strong>Results: </strong>The study included 336 patients (227 with neuroendocrine carcinoma and 109 with mixed adenoneuroendocrine carcinoma). The average age was 62.7 years. The cohort comprised 80 (24.7%) patients in stage I, 146 (42.9%) in stage II, 62 (18.1%) in stage III, and 48 (14.3%) in stage IV. Significant differences in OS were observed across tumor-node-metastasis stages (<i>P</i> < 0.001). Multivariate analysis showed age, Ki-67 index, invasion depth, lymph node metastasis, distant metastasis, and platelet-to-lymphocyte ratio as independent risk factors. We developed a nomogram with a concordance index of 0.779 (95% confidence interval: 0.743-0.858). Receiver operating characteristic analysis showed area under the curves for 1-year, 3-year, and 5-year OS predictions of 0.865, 0.850, and 0.890, respectively. The calibration curve demonstrated good agreement with actual outcomes. The area under the UDC for the nomogram <i>vs</i> the 8^th American Joint Committee on Cancer tumor-node-metastasis staging system were 0.047 <i>vs</i> 0.027, 0.291 <i>vs</i> 0.179, and 0.376 <i>vs</i> 0.216 for 1-year, 3-year, and 5-year OS, respectively.</p><p><strong>Conclusion: </strong>PDGNENs are predominantly found in older men, often in advanced stages at diagnosis, resulting in poor prognosis. The established nomogram demonstrates strong predictive capability and clinical utility.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102565"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudomyxoma peritonei originating from small intestine: A case report and review of literature.","authors":"Guan-Jun Shi, Chong Wang, Pu Zhang, Yi-Yan Lu, Hai-Peng Zhou, Rui-Qing Ma, Lu-Biao An","doi":"10.5306/wjco.v16.i4.103564","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.103564","url":null,"abstract":"<p><strong>Background: </strong>Pseudomyxoma peritonei (PMP) is a distinct form of peritoneal malignancy characterized by diffuse intra-abdominal gelatinous ascites, with an estimated incidence of 1-3 per 1000000. PMP is predominantly secondary to appendiceal mucinous neoplasms, with rarer origins including the ovaries, colon, and urachus. However, PMP originating from small intestine is extremely rare.</p><p><strong>Case summary: </strong>A 60-year-old male patient presented with anorexia and abdominal distension. Computed tomography revealed the presence of abdominopelvic effusions and multiple intra-abdominal space-occupying lesions. Ultrasound-guided aspiration indicated that the aspirated tissue was mucinous. Exploratory laparoscopy and tissue biopsy identified diffuse tumor nodules in peritoneum, omentum, pelvic region, intestinal walls, and mesentery. Histopathological analysis of the resected tumors confirmed the presence of mucinous adenocarcinoma, but the primary lesion was difficult to determine. The patient was referred to our center for further treatment and underwent cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) under general anesthesia. The intraoperative peritoneal cancer index was 30. The surgery lasted 8 hours, with a blood loss of about 600 mL. A complete cytoreduction (CCR0) was achieved. No serious complications occurred after surgery, and the patient's condition was good during the telephone follow-up. Postoperative pathology confirmed the diagnosis of small intestinal mucinous adenocarcinoma at proximal jejunum, which was complicated by high-grade PMP.</p><p><strong>Conclusion: </strong>PMP originating from small intestine is an exceptionally rare entity that exhibits non-specific clinical features. The preferred treatment is CRS + HIPEC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"103564"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a nomogram-based risk prediction model for depressive symptoms in middle-aged and young breast cancer patients.","authors":"Ye Mao, Rui-Xin Shi, Lei-Ming Gao, An-Ying Xu, Jia-Ning Li, Bei Wang, Jun-Yuan Wu","doi":"10.5306/wjco.v16.i4.102208","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102208","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is the second most common malignancy globally. Young and middle-aged patients face more pressures from diagnosis, treatment, costs, and psychological issues like self-image concerns, social barriers, and professional challenges. Compared to other age groups, they have higher recurrence rates, lower survival rates, and increased risk of depression. Research is lacking on factors influencing depressive symptoms and predictive models for this age group.</p><p><strong>Aim: </strong>To analyze factors influencing depressive symptoms in young/middle-aged BC patients and construct a depression risk predictive model.</p><p><strong>Methods: </strong>A total of 360 patients undergoing BC treatment at two tertiary hospitals in Jiangsu Province, China from November 2023 to April 2024 were included in the study. Participants were surveyed using a general information questionnaire, the patient health questionnaire depression scale, the visual analog scale for pain, the revised family support scale, and the long form of the international physical activity questionnaire. Univariate and multivariate analyses were conducted to identify the factors affecting depression in middle-aged and young BC patients, and a predictive model for depression risk was developed based on these findings.</p><p><strong>Results: </strong>Among the 360 middle-aged and young BC patients, the incidence rate of depressive symptoms was 38.61% (139/360). Multivariate analysis revealed that tumor grade, patient's monthly income, pain score, family support score, and physical activity score were factors influencing depression in this patient group (<i>P</i> < 0.05). The risk prediction model constructed based on these factors yielded an area under the receiver operating characteristic curve of 0.852, with a maximum Youden index of 0.973, sensitivity of 86.80%, specificity of 89.50%, and a diagnostic odds ratio of 0.552. The Hosmer-Lemeshow test for goodness of fit indicated an adequate model fit (<i>χ</i> ² = 0.360, <i>P</i> = 0.981).</p><p><strong>Conclusion: </strong>The constructed predictive model demonstrates good predictive performance and can serve as a reference for medical professionals to early identify high-risk patients and implement corresponding preventive measures to decrease the incidence of depressive symptoms in this population.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102208"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Checkpoint kinase 1 as a promising target in colorectal cancer management.","authors":"Wenxue Ma, Natalia Baran","doi":"10.5306/wjco.v16.i4.104213","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.104213","url":null,"abstract":"<p><p>This editorial provides insights into the pivotal role of checkpoint kinase 1 (CHEK1) as both a biomarker and therapeutic target in colorectal cancer (CRC), based on findings from a recent study by Pang <i>et al</i>. Using single-cell RNA sequencing and immunohistochemistry, the study demonstrates significant CHEK1 overexpression in CRC tissues and identifies nitidine chloride as a potent CHEK1 inhibitor that disrupts DNA damage repair pathways. These findings underscore the therapeutic potential of CHEK1 inhibition and highlight the need for further research to address gaps in CRC treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"104213"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report.","authors":"Hu-Cheng Yan, Yan Liu, You Feng, Jun-Ming Li, Lei-Ming Sheng, Xin Chen, Yu-Ping Xie, Na Li","doi":"10.5306/wjco.v16.i3.99527","DOIUrl":"10.5306/wjco.v16.i3.99527","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. In cases of metastatic CRC (mCRC) that are resistant to conventional chemotherapy-based treatments, the efficacy of available therapeutic options is typically low. CRC exhibiting overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) gene has shown responsiveness to HER2-targeted therapies.</p><p><strong>Case summary: </strong>We present the case of a 69-year-old woman diagnosed with mCRC with an NRAS p.G12V mutation and microsatellite stability, identified through tumor sequencing, along with HER2 overexpression detected by immunohistochemistry. She exhibited an excellent response to disitamab vedotin-containing therapy. To our knowledge, this is the first reported case of mCRC with HER2 overexpression and an NRAS p.G12V mutation achieving a remarkable clinical response to anti-HER2 therapy.</p><p><strong>Conclusion: </strong>Disitamab vedotin demonstrates promising anti-tumor effects in HER2-overexpressing mCRC, offering patients an additional treatment option.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 3","pages":"99527"},"PeriodicalIF":2.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the prognostic model for palliative radiotherapy in older patients with cancer.","authors":"Hyojung Park","doi":"10.5306/wjco.v16.i3.101705","DOIUrl":"10.5306/wjco.v16.i3.101705","url":null,"abstract":"<p><strong>Background: </strong>Older patients are more likely to have a poor performance status and comorbidities. There is a reluctance to extensively investigate and treat older patients. As elderly individuals and patients with neoplasms each increase in number, palliative treatment of older patients is expected to grow as an issue.</p><p><strong>Aim: </strong>To investigated the role of palliative radiotherapy in older patients and patients who were expected to demonstrate a therapeutic effect.</p><p><strong>Methods: </strong>From February 2019 to February 2022, 33 patients aged ≥ 80 years underwent palliative radiotherapy. The prognosis in palliative care study predictor (PiPS), palliative prognostic index (PPI), and delirium-palliative prognostic score (D-PaP) models were used for prognosis prediction. D-PaP scores calculated according to the doctor's prediction of clinical prediction of survival (CPS) were excluded and then analyzed for comparison. Radiation was prescribed at a dose of 2.5-7 Gy per fraction, up to a median of 39 Gy₁₀ (range, 28-75 Gy₁₀).</p><p><strong>Results: </strong>The median follow-up was 2.4 months (range, 0.2-27.5 months), and 28 patients (84.8%) showed subjective symptom improvements following treatment. The 2- and 6-month survival rates of all patients were 91.5% and 91.5%, respectively. According to regression analysis, the performance status index, symptom type, and radiation dose all showed no significant correlation with the treatment response. When survival was expected for > 55 days in the PiPS model, the 2-month survival rate was 94.4%. For patients with PPI and D-PaP-CPS values of 0-3.9 points, the 2-month survival rates were 90.0% and 100%, respectively. For patients with a score of ≥ 4 points, the 2-month survival rates were 37.5% and 0%, respectively.</p><p><strong>Conclusion: </strong>This study shows that the prognosis prediction model used in palliative care can be used to identify patients suitable for treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 3","pages":"101705"},"PeriodicalIF":2.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}